FN Clarivate Analytics Web of Science
VR 1.0
PT J
ID GROWTH-FACTOR-RECEPTOR; CELL LUNG-CANCER; METASTATIC COLORECTAL-CANCER;
   TYROSINE KINASE INHIBITOR; PHASE-III TRIAL; K-RAS MUTATION; PREVIOUSLY
   TREATED PATIENTS; ADVANCED PANCREATIC-CANCER; GENE COPY NUMBER;
   QUALITY-OF-LIFE
ER

PT J
ID RECEPTOR TYROSINE KINASE; GEFITINIB; INHIBITOR; MUTATIONS; COMBINATION;
   SMOKERS; TUMORS
ER

PT J
ID PROTEIN-PROTEIN INTERFACES; FACTOR-ALPHA; CRYSTAL-STRUCTURE;
   EXTRACELLULAR DOMAINS; MONOCLONAL-ANTIBODIES; KINASE-ACTIVITY; ERBB
   RECEPTORS; BREAST-CANCER; TUMOR-GROWTH; LUNG-CANCER
ER

PT J
ID NEU DIFFERENTIATION FACTOR; FACTOR RECEPTOR; MONOCLONAL-ANTIBODY; EGF
   RECEPTOR; ANDROGEN RECEPTOR; TYROSINE KINASE; CANCER CELLS; TRASTUZUMAB
   HERCEPTIN; PROTEIN EXPRESSION; GENE AMPLIFICATION
ER

PT J
ID ENDOTHELIAL GROWTH-FACTOR; SIGNAL-TRANSDUCTION; COMBINATION THERAPY;
   PROGENITOR CELLS; DRUG-RESISTANCE; TYROSINE KINASE; DENDRITIC CELLS;
   HUMAN MONOCYTES; RECEPTOR FLT-1; STEM-CELLS
ER

PT J
ID EPIDERMAL-GROWTH-FACTOR; CELL LUNG-CANCER; TYROSINE KINASE INHIBITORS;
   HUMAN-BREAST-CARCINOMA; ACQUIRED-RESISTANCE; TRASTUZUMAB RESISTANCE;
   EGFR MUTATIONS; HIGH-FREQUENCY; PI3K PATHWAY; PIK3CA GENE
ER

PT J
ID GROWTH-FACTOR RECEPTOR; TYROSINE KINASES; SH2 DOMAINS;
   SACCHAROMYCES-CEREVISIAE; WIDE PREDICTION; BREAST-CANCER;
   IDENTIFICATION; TRANSFORMATION; CARCINOMAS; EXPRESSION
ER

PT J
DE Akt; EGF receptor
ID EPIDERMAL-GROWTH-FACTOR; TYROSINE KINASE INHIBITOR; FACTOR-RECEPTOR;
   ZD1839 IRESSA; PHOSPHATIDYLINOSITOL 3-KINASE; WIDE PREDICTION; EGFR
   MUTATIONS; TUMOR-CELLS; PATHWAYS; TRIAL
ER

PT J
ID EPIDERMAL-GROWTH-FACTOR; METASTATIC BREAST-CANCER; CELL LUNG-CANCER;
   TYROSINE KINASE INHIBITORS; HUMAN-TUMOR CELLS; PREVIOUSLY TREATED
   PATIENTS; NEU DIFFERENTIATION FACTOR; FACTOR RECEPTOR FAMILY;
   HUMAN-BRAIN TUMORS; PHASE-II TRIAL
ER

PT J
ID EPIDERMAL-GROWTH-FACTOR; CELL LUNG-CANCER; METASTATIC BREAST-CANCER;
   TYROSINE KINASE INHIBITOR; GENE COPY NUMBER; PERTUZUMAB PLUS
   TRASTUZUMAB; POLARIZED EPITHELIAL-CELLS; MUTANT COLORECTAL CANCERS;
   FACTOR-I RECEPTOR; ACQUIRED-RESISTANCE
ER

PT J
ID EPIDERMAL-GROWTH-FACTOR; TYROSINE KINASE; TRANSMEMBRANE DOMAIN;
   CRYSTAL-STRUCTURE; PLASMA-MEMBRANE; COILED-COIL; DIMERIZATION;
   INHIBITOR; MUTATIONS; LIGAND
ER

PT J
ID GROWTH-FACTOR RECEPTOR; METASTATIC BREAST-CANCER; CELL LUNG-CANCER; DRUG
   CONJUGATE; GEMTUZUMAB OZOGAMICIN; TRASTUZUMAB EMTANSINE;
   MONOCLONAL-ANTIBODIES; EFFECTOR FUNCTIONS; COLORECTAL-CANCER; CYTOTOXIC
   DRUG
ER

PT J
ID EPIDERMAL GROWTH-FACTOR; LIGAND-BINDING SPECIFICITY; FACTOR RECEPTOR;
   EGF RECEPTOR; PROTEIN STRUCTURES; SIGNALING NETWORK; DOMAIN; EXPRESSION;
   AFFINITY; MODEL
ER

PT J
ID PHAGE-DISPLAY TECHNOLOGY; KINASE DOMAIN RECEPTOR; CRYSTAL-STRUCTURE;
   ANGIOGENIC SWITCH; ANGSTROM RESOLUTION; PROMOTER ACTIVITY; FLT-1
   RECEPTOR; CELLS; CARCINOGENESIS; BEVACIZUMAB
ER

PT J
ID ENDOTHELIAL GROWTH-FACTOR; SOMATIC HYPERMUTATION; BREAST-CANCER;
   ANGSTROM RESOLUTION; CRYSTAL-STRUCTURE; MOLECULAR-BASIS; RECEPTOR;
   COMPLEX; XENOGRAFTS; DIVERSITY
ER

PT J
ID CD8(+) T-CELLS; CHIMERIC ANTIGEN RECEPTOR; LONG-TERM SURVIVAL;
   REGULATORY T; ANTITUMOR-ACTIVITY; CTLA-4 BLOCKADE; PD-1 BLOCKADE;
   UP-REGULATION; B7 FAMILY; CALRETICULIN EXPOSURE
ER

PT J
ID GROWTH-FACTOR-RECEPTOR; CHRONIC MYELOID-LEUKEMIA; CELL LUNG-CANCER;
   GASTROINTESTINAL STROMAL TUMORS; BCR-ABL; DRUG-RESISTANCE; GENE
   MUTATION; IMATINIB RESISTANCE; DOMAIN MUTATIONS; EGFR MUTATIONS
ER

PT J
ID GROWTH-FACTOR RECEPTOR; CELL LUNG-CANCER; METASTATIC COLORECTAL-CANCER;
   TYROSINE KINASE INHIBITORS; MONOCLONAL-ANTIBODY; ACQUIRED-RESISTANCE;
   ACTIVATION; THERAPY; GEFITINIB; ERBB3
ER

PT J
DE Bispecific antibodies; Antibody engineering; Antibody therapeutics
ID GROWTH-FACTOR RECEPTOR; VARIABLE-DOMAIN IMMUNOGLOBULIN; FAB-ARM
   EXCHANGE; MULTIPLE DISEASE MEDIATORS; SINGLE-CHAIN DIABODY;
   ANTIGEN-BINDING; T-CELLS; MONOCLONAL-ANTIBODIES; HETERODIMER FORMATION;
   INHIBITORY-ACTIVITY
ER

PT J
ID VARIABLE-DOMAIN IMMUNOGLOBULIN; HEMOPHILIA-A MODEL; ANTIGEN-BINDING;
   GROWTH-FACTOR; T-CELLS; IGG ANTIBODIES; TUMOR-CELLS; IN-VITRO;
   MULTIFUNCTIONAL STRUCTURES; TRIFUNCTIONAL ANTIBODIES
ER

PT J
ID EPIDERMAL-GROWTH-FACTOR; TYROSINE KINASE INHIBITORS; MAMMARY
   EPITHELIAL-CELLS; FACTOR RECEPTOR; BREAST-CANCER; ACINAR ARCHITECTURE;
   SOMATIC MUTATIONS; SIGNALING NETWORK; CRYSTAL-STRUCTURE; COLON
   CARCINOMAS
ER

PT J
DE EGFR; human epidermal growth factor receptor 3; human epidermal growth
   factor receptor4; receptor oligomerization
ID EPIDERMAL-GROWTH-FACTOR; CRYSTAL-STRUCTURE; BINDING; PROTEIN;
   ACTIVATION; MECHANISM; HER3; FAMILY; CONFORMATION; INHIBITION
ER

PT J
ID CELL LUNG-CANCER; GROWTH-FACTOR RECEPTOR; PHASE-III TRIAL; METASTATIC
   PANCREATIC-CANCER; TYROSINE KINASE INHIBITORS; HUMAN TUMOR XENOGRAFTS;
   CLINICAL-TRIALS; K-RAS; COLORECTAL-CANCER; PLUS GEMCITABINE
ER

PT J
ID GROWTH-FACTOR RECEPTOR; TYROSINE KINASE INHIBITOR; METASTATIC
   BREAST-CANCER; ENHANCED ANTITUMOR-ACTIVITY; ADVANCED COLORECTAL-CANCER;
   PHASE-II TRIAL; LUNG-CANCER; MONOCLONAL-ANTIBODY; ACQUIRED-RESISTANCE;
   EGFR INHIBITORS
ER

PT J
DE Epidermal growth factor receptor; EGFR inhibitor; Skin toxicity; Rash;
   Phosphatase inhibitor; Menadione
ID CELL LUNG-CANCER; TYROSINE KINASE INHIBITOR; METASTATIC
   COLORECTAL-CANCER; SEVERE CUTANEOUS REACTION; CLINICAL-TRIALS GROUP;
   PHASE-III TRIAL; EGFR INHIBITORS; NECK-CANCER; CHEMOKINE EXPRESSION;
   SUPPORTIVE CARE
ER

PT J
DE phage display; affinity improvements; antibody engineering; designed CDR
ID BY-PASSING IMMUNIZATION; ANTIGEN INTERACTIONS; ANTI-P185HER2 ANTIBODY;
   HYPERVARIABLE REGIONS; CRYSTAL-STRUCTURE; RIBOSOME DISPLAY; SELECTION;
   FRAGMENTS; SITE; REPERTOIRES
ER

PT J
ID DEPENDENT CELLULAR CYTOTOXICITY; FC-GAMMA-RIII; C-RECEPTOR
   POLYMORPHISMS; HAMSTER OVARY CELLS; IMMUNOGLOBULIN-G;
   MONOCLONAL-ANTIBODY; OVEREXPRESSING HER2; IGG1 ANTIBODIES; BINDING;
   CHEMOTHERAPY
ER

PT J
ID KINASE DOMAIN RECEPTOR; CRYSTAL-STRUCTURE; ANGSTROM RESOLUTION; TYROSINE
   KINASE; BINDING; VEGF; ANGIOGENESIS; ANTIBODY; COMPLEX; TUMOR
ER

PT J
ID B-CELL LYMPHOMA; EGF RECEPTOR; MICE; IGG; XENOGRAFTS; INHIBITION;
   COMPLEMENT; METABOLISM
ER

PT J
ID CELLS; GENERATION; INDUCTION; EGFR
ER

PT J
ID EPIDERMAL-GROWTH-FACTOR; C-ERBB-3 PROTEIN EXPRESSION; HUMAN
   BREAST-CANCER; RECEPTOR TYROSINE KINASES; HUMAN PANCREATIC-CANCER; ERBB
   FAMILY-MEMBERS; CLEAR-CELL SARCOMA; FACTOR-I RECEPTOR; LUNG-CANCER;
   PHOSPHATIDYLINOSITOL 3-KINASE
ER

PT J
ID FIBERS; COMPOSITES
ER

PT J
DE Appended IgG; bispecific antibodies; Fab; Fc heterodimerization; fusion
   proteins; immunoglobulin; scFv
ID SINGLE-CHAIN ANTIBODY; VARIABLE-DOMAIN IMMUNOGLOBULIN; GROWTH-FACTOR
   RECEPTOR; DEPENDENT CELLULAR CYTOTOXICITY; HETERODIMERIC IGG ANTIBODIES;
   ACUTE LYMPHOBLASTIC-LEUKEMIA; CRITICAL QUALITY ATTRIBUTES; SUPERIOR
   ANTITUMOR-ACTIVITY; MULTIPLE DISEASE MEDIATORS; TARGETED PAYLOAD
   DELIVERY
ER

PT J
ID VARIABLE-DOMAIN IMMUNOGLOBULIN; C-MET; HEPATOCYTE GROWTH;
   ESCHERICHIA-COLI; EGFR; IGG; AMPLIFICATION; HETERODIMERS; MOLECULES;
   EXCHANGE
ER

PT J
ID TYROSINE KINASE INHIBITOR; FACTOR RECEPTOR EGFR; LUNG-CANCER; THERAPY;
   FAMILY; GEFITINIB; CETUXIMAB; ANTIBODY; CELLS; DISCONTINUATION
ER

PT J
ID METASTATIC COLORECTAL-CANCER; TYROSINE KINASE INHIBITOR; ANTIANGIOGENIC
   THERAPY; PHASE-III; BEVACIZUMAB; ANGIOGENESIS; SURVIVAL; MODEL; MICE;
   CARCINOGENESIS
ER

PT J
ID TYROSINE KINASE INHIBITOR; ERBB3 GENE-PRODUCT; LUNG-CANCER;
   PROTEIN-KINASE; K-RAS; PHOSPHATIDYLINOSITOL 3-KINASE; THERAPEUTIC
   TARGET; SIGNALING PATHWAY; EGF RECEPTOR; ERK ACTIVITY
ER

PT J
ID METASTATIC BREAST-CANCER; EPIDERMAL-GROWTH-FACTOR; RECEPTOR DIMERIZATION
   INHIBITOR; SINGLE-AGENT PERTUZUMAB; PHASE-II; PLUS DOCETAXEL;
   UP-REGULATION; LUNG-CANCER; RHUMAB 2C4; ERBB3
ER

PT J
DE antibody; bispecific; light chain; heavy chain; knobs-into-holes;
   heterodimerization; CrossMab; DAF
ID FAB-ARM EXCHANGE; C-MET ANTIBODY; THERAPEUTIC ANTIBODIES;
   MONOCLONAL-ANTIBODIES; T-CELLS; IN-VIVO; DOMAIN; RECEPTOR;
   IMMUNOGLOBULIN; ACTIVATION
ER

PT J
DE angiogenesis; gene knockin; tumor
ID ENDOTHELIAL GROWTH-FACTOR; CRYSTAL-STRUCTURE; ANTIANGIOGENIC THERAPY;
   NEUTRALIZING ANTIBODY; TUMOR VASCULATURE; MOUSE MODEL; CANCER;
   BEVACIZUMAB; INHIBITION; ANGIOGENESIS
ER

PT J
ID CANCER-THERAPY; TUMOR-CELLS; T-CELLS; FRAGMENTS; IDENTIFICATION;
   RESIDUES; CODE; FAB
ER

PT J
ID GROWTH-FACTOR RECEPTOR; FC-GAMMA-RIIIA; MONOCLONAL-ANTIBODY; PHASE-I;
   BISPECIFIC ANTIBODIES; CLINICAL DEVELOPMENT; ANTI-CD20 ANTIBODY; SOLID
   TUMORS; HUMAN CD20; CELL
ER

PT J
DE bispecific antibody; cetuximab; panitumumab; immunotherapy
ID TUMOR-GROWTH; CETUXIMAB; CONSTRUCTS; INHIBITION; MICE
ER

PT J
ID SHEET/BISMALEIMIDE NANOCOMPOSITES; MECHANICAL-PROPERTIES; MACROSCOPIC
   FIBERS; POLYMER COMPOSITES; HIGH-STRENGTH; PERFORMANCE; LOAD
ER

PT J
DE Carbon nanotubes; Nanocomposites; Polymer-matrix composites (PMCs);
   Mechanical properties; Electrical properties
ID CARBON-NANOTUBE FIBERS; REINFORCED NYLON-6 COMPOSITES; POLYMER
   COMPOSITES; SHEET/BISMALEIMIDE NANOCOMPOSITES; MORPHOLOGY; WAVINESS;
   ARRAYS; YARNS; PERFORMANCE; MATRIX
ER

PT J
DE antibody library; phage display; protein engineering; affinity;
   specificity
ID COMPLEMENTARITY-DETERMINING REGIONS; SPECIFICITY-DETERMINING RESIDUES;
   MACROMOLECULAR CRYSTALLOGRAPHY; MOLECULAR RECOGNITION; BINDING-SITE;
   IDENTIFICATION; IMMUNOGLOBULIN; REPERTOIRES; LIBRARIES; SOFTWARE
ER

PT J
ID HER2-POSITIVE BREAST-CANCER; TYROSINE KINASE; LUNG-CANCER; EXTENDED
   5-SUBSTITUENT; ADJUVANT CHEMOTHERAPY; SELECTIVE INHIBITORS; MET
   AMPLIFICATION; OVARIAN-CANCER; PROTEIN; DOMAIN
ER

PT J
ID ENDOTHELIAL GROWTH-FACTOR; ALTERNATIVE BINDING-PROTEINS; HUMAN
   NEUTROPHIL ELASTASE; ANKYRIN REPEAT PROTEINS; HIGH-AFFINITY BINDING;
   CYSTINE-KNOT PEPTIDE; IN-VIVO; BISPECIFIC ANTIBODIES; AFFIBODY
   MOLECULES; HEREDITARY ANGIOEDEMA
ER

PT J
ID TRANSMISSION LOSS; SANDWICH PANELS
ER

PT J
DE Epidermal growth factor receptor; EGFR; ErbB1; Human epidermal growth
   factor receptor 1; Monoclonal antibodies; Small molecule inhibitors;
   Head and neck squamous cell carcinoma
ID LOCALLY ADVANCED HEAD; TYROSINE KINASE INHIBITOR; RANDOMIZED PHASE-II;
   RECOMBINANT HUMAN INTERLEUKIN-12; COOPERATIVE-ONCOLOGY-GROUP;
   MONOCLONAL-ANTIBODY; EGFR-INHIBITOR; ANTITUMOR-ACTIVITY; PLUS CETUXIMAB;
   PRECLINICAL PHARMACOKINETICS
ER

PT J
ID TIME-REVERSAL MIRROR; LAMB WAVES
ER

PT J
ER

PT J
ID LUNG-CANCER; BREAST-CANCER; ACQUIRED-RESISTANCE; TUMOR-CELL; GROWTH;
   GEFITINIB; SENSITIVITY; HER2; EXPRESSION; MUTATIONS
ER

PT J
ID NON-HODGKINS-LYMPHOMA; CHRONIC LYMPHOCYTIC-LEUKEMIA; COLONY-STIMULATING
   FACTOR; HUMANIZED ANTI-CD22 ANTIBODY; SYSTEMIC-LUPUS-ERYTHEMATOSUS;
   FC-GAMMA-RIII; RHEUMATOID-ARTHRITIS; MONOCLONAL-ANTIBODIES; RITUXIMAB
   TREATMENT; AUTOIMMUNE-DISEASE
ER

PT J
DE Bispecific; cancer therapy; immunotherapy; retargeting; single domain
   antibodies
ID GROWTH-FACTOR RECEPTOR; FC-GAMMA-RIII; LASTING ANTITUMOR IMMUNITY;
   NON-HODGKINS-LYMPHOMA; NATURAL-KILLER-CELLS; PHASE-I TRIAL;
   MONOCLONAL-ANTIBODY; T-CELLS; DOMAIN ANTIBODIES; TUMOR-GROWTH
ER

PT J
ID ENDOTHELIAL GROWTH-FACTOR; MULTIPLE INTESTINAL NEOPLASIA; RENAL-CELL
   CARCINOMA; MOUSE MODEL; ADENOMATOUS POLYPOSIS; TUMOR DORMANCY; KNOCKOUT
   MICE; COLON-CANCER; IN-VIVO; VILLIN
ER

PT J
ID NECROSIS-FACTOR FAMILY; LYMPHOCYTE STIMULATOR; T-CELL;
   MONOCLONAL-ANTIBODY; RECEPTOR BINDING; SURVIVAL FACTOR; TNF RECEPTOR;
   TACI; LIGAND; ACTIVATION
ER

PT J
DE flexoelectricity; microcantilevers; (Ba,Sr)TiO3; sensors
ID FORCE MICROSCOPY
ER

PT J
ID ESCHERICHIA-COLI; DOMAIN INTERFACE; STRUCTURAL BASIS; ASTHMA; RECEPTOR;
   LEBRIKIZUMAB; HETERODIMERS; PATHOGENESIS; ANTAGONISTS; BLOCKADE
ER

PT J
ID HIV-1 MONOCLONAL-ANTIBODY; MOLECULAR RECOGNITION; THERMODYNAMIC
   ANALYSIS; MUTATIONAL ANALYSIS; BINDING INTERFACES; CRYSTAL-STRUCTURE;
   CROSS-REACTIVITY; PROTEIN DYNAMICS; RECEPTOR-BINDING; FAB
ER

PT J
DE ranibizumab; aflibercept; bevacizumab; VEGF; affinity; analytical
   ultracentrifugation
ID SURFACE-PLASMON RESONANCE; SIZE-DISTRIBUTION ANALYSIS; MACULAR
   DEGENERATION; VEGF-TRAP; ANALYTICAL ULTRACENTRIFUGATION; RANIBIZUMAB;
   BEVACIZUMAB; THERAPY; LIGANDS; MODEL
ER

PT J
ID ENDOTHELIAL GROWTH-FACTOR; PROMOTES TUMOR-METASTASIS; SENTINEL-NODE
   BIOPSY; CELL LUNG-CANCER; BREAST-CANCER; NEOADJUVANT CHEMOTHERAPY;
   VASCULAR-PERMEABILITY; INDOCYANINE GREEN; LYMPHANGIOGENESIS; CARCINOMA
ER

PT J
ID CETUXIMAB; BEVACIZUMAB; TRIAL; CHEMOTHERAPY; OXALIPLATIN; IRINOTECAN
ER

PT J
ID GROWTH-FACTOR RECEPTOR; TYROSINE KINASE INHIBITOR; ZD1839; TRIAL;
   EXPRESSION; CELLS; CHEMOTHERAPY; DOCETAXEL; TUMORS; IRESSA
ER

PT J
DE Cryptanalysis; Chaotic system; Image encryption; Hyper-chaos
ID ALGORITHM; MAPS
ER

PT J
ER

PT J
DE Fe-B alloy; Interface reaction; Microcrack; Corrosion; Molten zinc
ID LIQUID ZINC; STAINLESS-STEEL; IRON; ALUMINUM; SURFACE; CARBON; PHASES;
   FE3AL
ER

PT J
ID ENDOTHELIAL GROWTH-FACTOR; BONE-MARROW MICROENVIRONMENT;
   IMMUNOGLOBULIN-LIKE DOMAIN; FACTOR RECEPTOR-1; TYROSINE KINASE;
   PATHOLOGICAL CONDITIONS; VASCULAR ENDOTHELIUM; TUMOR ANGIOGENESIS;
   PRECURSOR CELLS; STEM-CELLS
ER

PT J
ID LEAD-ZIRCONATE-TITANATE; DIELECTRIC-PROPERTIES; FERROELECTRICITY
ER

PT J
ER

PT J
ID FRACTURES
ER

PT J
ID FATIGUE; PROGNOSTICS; SYSTEMS; MODEL
ER

PT J
DE Piezoelectric wafer; d(36) type; Shear horizontal wave; Frequency
   tuning; Actuator and sensor
ID LAMB WAVES
ER

PT J
ID CELL LUNG-CANCER; MULTICENTER RANDOMIZED-TRIAL; PREVIOUSLY TREATED
   PATIENTS; III TRIAL; FLUOROURACIL-LEUCOVORIN; SOLID TUMORS; GEFITINIB;
   OXALIPLATIN; ERLOTINIB; THERAPY
ER

PT J
DE intravitreal; bispecifics; rabbits; mathematical model
ID ENDOTHELIAL GROWTH-FACTOR; NEONATAL FC-RECEPTOR; MACULAR DEGENERATION;
   ESCHERICHIA-COLI; RANIBIZUMAB; EXPRESSION; FRAGMENT; ANGIOGENESIS;
   BEVACIZUMAB; VEGF
ER

PT J
DE guided wave; damage detection; in-plane shear; piezoelectric wafer
ID FUNDAMENTAL TORSIONAL MODE; LAMB WAVES; CRACK
ER

PT J
DE Flexoelectric; accelerometer; barium strontium titanate; flexoelectric
   unimorph
ID THIN-FILMS; PIEZOELECTRIC COEFFICIENT; TITANATE; POLARIZATION; CRYSTALS
ER

PT J
ID BROADLY NEUTRALIZING ANTIBODIES; TYROSINE KINASE INHIBITORS; HIV-1
   MONOCLONAL-ANTIBODY; GROWTH-FACTOR RECEPTOR; CROSS-REACTIVITY;
   STRUCTURAL BASIS; MOLECULAR-BASIS; CELL-LINES; BINDING; CANCER
ER

PT J
DE elliptic curve cryptosystem; key management scheme; hierarchical access
   control
ER

PT J
DE epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI);
   gefitinib; personalized medicine; biomarker; FISH
ID GROWTH-FACTOR RECEPTOR; LUNG-CANCER PATIENTS; TYROSINE KINASE;
   CARCINOMA; MUTATIONS; TRIAL; GENE; INHIBITORS; SURVIVAL; ZD1839
ER

PT J
ID MULTIPLE INTESTINAL NEOPLASIA; ENDOTHELIAL GROWTH-FACTOR; COLON-CANCER;
   MOUSE MODELS; K-RAS; MOLECULAR REGULATION; HEPATIC METASTASES;
   TUMOR-FORMATION; CELLS; EXPRESSION
ER

PT J
DE Damage identification; composite structures; reverse-time migration;
   zero-lag cross-correlation imaging condition; laser Doppler vibrometer
ID ACOUSTIC-EMISSION; LAMB WAVES; HEALTH; PLATE; DELAMINATION
ER

PT J
ID COMPOSITE PLATES; WAVE-PROPAGATION; FORCE; DECONVOLUTION; SENSORS
ER

PT J
DE antibody libraries; diversity design; hybridoma; synthetic antibodies
ID PHAGE DISPLAY LIBRARY; COMPLEMENTARITY-DETERMINING REGIONS; AFFINITY
   HUMAN-ANTIBODIES; GROWTH-HORMONE-RECEPTOR; SINGLE-FRAMEWORK SCAFFOLD;
   SITE-SPECIFIC PEGYLATION; ANTIGEN-BINDING DOMAINS; FC-GAMMA-RIII;
   MONOCLONAL-ANTIBODY; NECROSIS-FACTOR
ER

PT J
ID ENDOTHELIAL GROWTH-FACTOR; COMPLEMENTARITY-DETERMINING REGIONS; 2-IN-ONE
   ANTIBODY; MATURATION; BINDING; LIBRARIES; ANTIGEN; VEGF; FAB;
   IMMUNOGLOBULINS
ER

PT J
ID MODE CONVERSION; ELEMENT SOLUTION; ELASTIC PLATE; REFLECTION; INCIDENT
ER

PT J
DE dual specific antibody; bispecific antibody; Dual Action Fab; phage
   display; IL5
ID ANTIGEN-BINDING SITE; SCANNING MUTAGENESIS; RECEPTOR; CYTOKINES;
   LIBRARIES; AFFINITY; DISPLAY; ASTHMA
ER

PT J
DE Miniature wind turbine; Energy harvesting; Physics-based model; Wireless
   sensor
ID ENERGY-CONVERSION SYSTEM; GENERATION; POWER; OUTPUT
ER

PT J
DE magnetostriction sensor; ultrasonic stress wave; structure health
   monitoring; optimization design
ID ELECTROMAGNETIC ACOUSTIC TRANSDUCER; LAMB WAVE; STEEL; TECHNOLOGY
ER

PT J
DE electromagnetic migration algorithm; structural health monitoring;
   damage imaging; prestack; poststack; finite difference method
ID REVERSE-TIME MIGRATION; NONDESTRUCTIVE EVALUATION; OPTIMIZATION
   TECHNIQUE; MICROWAVE; DOMAIN; INVERSION; COMPOSITES; MEDIA; NDE
ER

PT J
DE Impact location detection; impact force reconstruction; time-reversal
   method; calibration spacing; noise effect
ID COMPOSITE PLATES; FORCE; SENSORS; DECONVOLUTION; EVENTS
ER

PT J
ID PROPAGATION; SYSTEM; PLATE; ARRAY
ER

EF